Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;2(2):73-82.
doi: 10.1177/2040620711402533.

Salvage therapy for relapsed or refractory acute myeloid leukemia

James K Mangan  1 , Selina M Luger
Affiliations

Salvage therapy for relapsed or refractory acute myeloid leukemia

James K Mangan et al. Ther Adv Hematol. 2011 Apr.

Abstract

There are a significant number of patients diagnosed with acute leukemia who either fail to achieve remission or who relapse thereafter. Challenges in treating this patient population include accurately assessing prognosis of disease and whether remission can be achieved; assessing the ability of patients to tolerate aggressive salvage therapies; choosing a salvage therapy that is most likely to succeed; and identifying suitable patients for hematopoietic stem cell transplantation. Despite the development of a variety of new investigational therapies, relapsed or refractory acute myeloid Leukemia remains a difficult clinical problem. Clinicians will need to consider all currently available approaches, including cytotoxic chemotherapy, targeted agents, and allogeneic stem cell transplantation, to optimize outcomes.

Keywords: acute myeloid leukemia; relapsed or refractory; salvage therapy.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Archimbaud E., Thomas X., Leblond V., Michallet M., Fenaux P., Cordonnier C., et al. (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone and cytarabine-86 trial. J Clin Oncol 13: 11–18 - PubMed
    1. Armistead P.M., de Lima M., Pierce S., Qiao W., Wang X., Thall P.F., et al. (2009) Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15: 1431–1438 - PMC - PubMed
    1. Becker P.S., Estey E., Petersdorf S., Storer B.E., Appelbaum F.R. (2009) G-CSF priming, clofarabine, and high-dose cytarabine (GCLAC) for relapsed or refractory acute myeloid leukemia (AML). Blood 114: Abstract 2068.
    1. Blum W., Klisovic R.B., Becker H., Yang X., Rozewski D.M., Phelps M.A., et al. (2010) Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 28: 4919–4925 - PMC - PubMed
    1. Bolanos-Meade J., Smith B.D., Gore S.D., McDevitt M.A., Luznik L., Fuchs E.J., et al. (2010) 5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 15 October [epub ahead of print]. - PMC - PubMed

LinkOut - more resources